{"schema_version":"secwatch.filing_event.v1","accession":"0000929638-24-001513","form_type":"8-K","ticker":"ICU","cik":"0001831868","company_name":"SeaStar Medical Holding Corp","filed_at":"2024-04-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.542179+00:00","generated_at":"2026-06-03T21:48:33.444334+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"SeaStar Medical reports 2023 net loss $26.2M; first FDA approval for Quelimmune pediatric device","bullets":["Net loss $26.2M ($1.21/share) in 2023 vs $12.2M ($1.48/share) in 2022; cash $176K at Dec 31, 2023.","FDA approved SCD-Pediatric (Quelimmune) in Feb 2024 for pediatric AKI with sepsis; distribution via Nuwellis.","NEUTRALIZE-AKI adult trial enrolled 24 subjects; interim analysis expected H2 2024 after 100 reach 90-day endpoint.","Appointed David A. Green as CFO in Jan 2024; completed $9.0M registered direct offering same month.","Restated 2022 financials (non-cash items); minimal impact on cash/operations."],"urls":{"canonical":"https://secwatch.observer/filing/0000929638-24-001513","json":"https://secwatch.observer/filing/0000929638-24-001513.json","markdown":"https://secwatch.observer/filing/0000929638-24-001513.md","text":"https://secwatch.observer/filing/0000929638-24-001513.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831868/000092963824001513/0000929638-24-001513-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831868/000092963824001513/a8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T21:48:33.444334+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"66ef5a3d5f1b3a9f6eaac432109803916792b81a","claim":"SeaStar Medical Holding Corp reported financial results for the 12 months ended December 31, 2023.","evidence_excerpt":"SeaStar Medical Reports 2023 Financial Results and Provides a Business Update DENVER (April 17, 2024) – SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the 12 months ended December 31, 2023 and provides a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831868/000092963824001513/0000929638-24-001513-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the 12 months ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}